C57BL mice inoculated with radiation leukemia virus (RadLV) develop preleukemic cells long before the onset of leukemia. These cells are potentially immunogenic but fail to elicit an immune response in the host because of the appearance of virus-specific suppressor T cells. We have studied the effect of polysaccharide K (PSK) on the generation of RadLV-specific cell-mediated immune responses in vitro. Long-term exposure to PSK in culture potentiated the ability of immunized T cells to respond to a RadLV-induced lymphoma. It also abrogated the suppressive activity of suppressor T cells and simultaneously boosted the ability of reactive T cells to respond. The dual immunostimulating activity of PSK resulted in the generation of T cytotoxic lymphocytes that could lyse lymphoma cells in vitro. The results suggest that PSK could be used as a prophylactic immune response modifier in preleukemia.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Ben-David Y, Kotler M, Yefenof E (1987) Leukemogenic, immunogenic and genetic properties of a thymotropic radiation leukemia virus. Int J Cancer 39: 492–497
Ben-David Y, Yefenof E, Kotler M (1987) Clonal analysis of radiation leukemia virus (RadLV) induced leukemic and preleukemic cells. Cancer Res 47: 6590–6594
Ebihara K, Minamishima Y (1984) Protective effect of biological response modifiers on murine cytomegalovirus infection. J Virol 51: 17–122
Enrke MJ, Reino JM, Eppolito C, Mihich E (1983) The effect of PS-K, a protein bound polysaccharide on immune responses against allogeneic antigens. Int J Immunopharmacol 5: 35–42
Haas M (1974) Continuous production of radiation leukemia virus in C57BL thymoma tissue culture lines: purification of the leukemogenic virus. Cell 1: 79–83
Haran-Ghera N (1978) Spontaneous and induced preleukemia cells in C57BL/6 mice: brief communication. J Natl Cancer Inst 60: 707–710
Haran-Ghera N, Peled A (1979) Induction of leukemia in mice by irradiation and radiation leukemia B virus variants. Adv Cancer Res 30: 45–83
Hosokawa M, Mizukoshi T, Sugawara M, Kobayashi H (1985) Therapeutic effects of PS-K and Busulfan on the recurrent and metastatic diseases after the surgical removal of 3-methylcholanthrene-induced autochthonous tumors in C57BL/6 mice. Gann 76: 61–67
Kondo M, Kato H, Yokoe N, Matsumura N, Hotta T, Masasuke M (1978) Activation of the complement by immunostimulants, BCG, OK-432 (Picibanil), and PS-K (Krestin) in vitro. Gann 69: 699–702
Lieberman M, Kaplan HS (1959) Leukemogenic activity of filtrates from radiation induced lymphoid tumors of mice. Science 130: 387–388
Mizushima Y, Yuhki N, Hosokawa M, Kobayashi H (1982) Diminution of cyclophosphamide-induced suppression of antitumor immunity by an immunomodulator PS-K and combined therapeutic effects of PS-K and cyclophosphamide on transplanted tumor in rats. Cancer Res 42: 5176–5180
Nomoto K, Yoshikumi C, Matsunaga K, Fujii T, Takeya K (1975) Restoration of antibody-forming capacities by PS-K in tumor-bearing mice. Gann 66: 365–374
Torisu M, Hayashi Y, Ishimitsu T, Fujimura T, Iwasaki K, Katano M, Yamamoto H, Kimura Y. Takesue M, Motoharu K, Nomoto K (1990) Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) adminstration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother 31: 261–268
Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K, Orita K (1984) Krestin (PSK). Cance Treat Rev 11: 131–155
Tsurku S, Nomoto K (1983) Effects of PSK on specific tumor immunity to syngeneic tumor cells. J Clin Lab Immunol 4: 215–219
Yefenof E, Ben-David Y (1983) Suppressor and reactive lymphocytes in radiation leukemia virus (RadLV)-induced leukemogenesis. Cancer Immunol Immunther 16: 48–52
Yefenof E, Ben-David Y (1986) Immunity and suppression in radiation and RadLV induced leukemogenesis. Leukemia Res 10: 797–801
Yefenof E, Zilcha D (1983) High and low leukemogeneic variants of radiation leukemia virus (RadLV) differ in ability to induce tumor specific immune suppression. Int J Cancer 30: 355–359
Yefenof E, Meidav A, Kedar E (1980) In vitro generation of cytotoxic lymphocytes against radiation and radiation leukemia virus (RadLV) induced tumors: III. Suppression of anti tumor immunity in vitro by lymphocytes of mice undergoing RadLV induced leukemogenesis. J Exp Med 152: 1473–1483
Yefenof E, Tchakirov R, Kedar E (1980) In vitro generation of cytotoxic lymphocytes against radiation and radiation leukemia virus (RadLV) induced tumors: I. Role of viral antigenicity. Cancer Immunol Immunother 8: 171–178
Yefenof E, Ben-David Y, Kotler M (1984) High-and low-leukemogenic variants of the radiation leukemia virus (RadLV): immunogenic, suppressive and genetic properties in relation to leukemogenic activity. Int J Cancer 34: 875–882
Yefenof E, Ben-David Y, Kotler M (1988) Preleukemic cells induced by RadLV are of an oligoclonal nature. Leukemia 2: 97–101
About this article
Cite this article
Yefenof, E., Einat, E. & Klein, E. Potentiation of T cell immunity against radiation-leukemia-virus-induced lymphoma by polysaccharide K. Cancer Immunol Immunother 34, 133–137 (1991). https://doi.org/10.1007/BF01741348
- T cells
- RadLV lymphoma
- Immunomodulator PSK